Filing Flows › Oncotelic Therapeutics (OTLC) › Q2 2026
Oncotelic Therapeutics (OTLC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Oncotelic Therapeutics (OTLC) reported revenue of $250K for the second quarter 2026 (Q2 2026). Operating margin was -337.4%, net earnings $341K (136.4% of revenue).
Oncotelic Therapeutics, Q2 2026: revenue $250K, operating margin -337.4%, net earnings $341K, operating cash flow −$92K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $250K | — | — |
| Operating profit | −$844K | — | — |
| Net earnings | $341K | — | — |
| Operating cash flow | −$92K | — | — |
What changed
Revenue was $250K in Q2 2026.
Operating costs exceeded revenue by $844K, an operating margin of -337.4%. Net earnings were $388K ($341K including minority interests, which bore $47K of losses). The effective tax rate was 0.0%. Non-operating items added $1.2M, 347% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$92K. Non-cash charges added back $730K of share-based compensation. Working capital and other items used $1.2M.
Questions
What was Oncotelic Therapeutics' revenue in the second quarter 2026?
Oncotelic Therapeutics (OTLC) reported revenue of $250K for the second quarter 2026 (Q2 2026).
Was Oncotelic Therapeutics profitable in the second quarter 2026?
Operating loss was $844K (-337.4% of revenue) and net earnings $341K.